Compare NHTC & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHTC | CTSO |
|---|---|---|
| Founded | 1988 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 45.7M |
| IPO Year | 1999 | 2008 |
| Metric | NHTC | CTSO |
|---|---|---|
| Price | $3.07 | $0.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 24.7K | ★ 67.9K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | ★ 12.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,776,000.00 | $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $2.40 | $0.60 |
| 52 Week High | $5.48 | $1.39 |
| Indicator | NHTC | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 39.95 | 67.25 |
| Support Level | $2.95 | $0.61 |
| Resistance Level | $3.38 | $0.85 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 21.05 | 87.32 |
Natural Health Trends Corp is an international direct-selling and e-commerce company. It offers a line of products such as Wellness, Herbal, Beauty, Lifestyle, and Home. Wellness products include targeted nutrition for joint health, antioxidant support, digestive health, heart health, and vision health. Herbal products include anti-aging and hydrating cleansers, creams, lotions, serums, and toners. Lifestyle products improve the overall quality of life and support active, physical, and healthy lifestyles. Home products are designed to create a clean and natural living environment for the home. It generates a majority of its revenue from Hong Kong and the rest from China, Taiwan, Japan, the United States, and other regions.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.